Varenicline, an FDA-approved prescription smoking cessation aid, is an effective evidence-based treatment for reducing tobacco use among individuals with mental health and substance use challenges. Join the National Behavioral Health ...
National, state, and local-level data sources are essential to address tobacco-related disparities among individuals with mental health and substance use challenges. But, knowing how to find, understand and apply these ...
Individuals with mental health and substance use challenges have lower-than-average cancer screening rates and are at greater risk of developing colorectal cancer than the general population. Integrating conversations around mental ...
Do you want to strengthen partnerships and collaborations with mental health and substance use treatment systems and providers to address tobacco-related disparities? Join us on May 10th, 2:30 – 3:30 p.m. ...
Join the National Behavioral Health Network for Tobacco and Cancer Control on Wednesday, May 11, 2:00 – 3:00 p.m. ET for a webinar designed to support organizations on addressing barriers ...
Addressing Tobacco Use and Mental Health Challenges in Pregnant Individuals: Part 1 Pregnant and postpartum individuals with mental health (MH) challenges who use tobacco encounter stigma and shame. As ...
Using an Intersectional Framework to Address Tobacco Use Disparities Intersectionality is a framework that examines how a person’s different social and political identities interact to influence their experiences of discrimination ...
Trauma-informed Cancer Care for Individuals with Mental Health and Substance Use Challenges When a cancer diagnosis is coupled with mental health or substance use challenges, care can be complex. Navigating ...
Leveraging Trauma-informed Motivational Interviewing in Tobacco Treatment and Control Individuals who experienced trauma, including adverse childhood experiences (ACEs), are disproportionately impacted by commercial tobacco use and often experience additional challenges ...
